Ascendis Pharma A/S

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ASND and other ETFs, options, and stocks.

About ASND

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes in its TransCon technologies to develop new therapies that address unmet medical needs. 

CEO
Jan Møller Mikkelsen
CEOJan Møller Mikkelsen
Employees
Employees
Headquarters
Hellerup, Capital Region
HeadquartersHellerup, Capital Region
Founded
2006
Founded2006
Employees
Employees

ASND Key Statistics

Market cap
16.64B
Market cap16.64B
Price-Earnings ratio
28.51
Price-Earnings ratio28.51
Dividend yield
Dividend yield
Average volume
1.24M
Average volume1.24M
High today
$273.80
High today$273.80
Low today
$266.65
Low today$266.65
Open price
$269.86
Open price$269.86
Volume
626.37K
Volume626.37K
52 Week high
$274.89
52 Week high$274.89
52 Week low
$160.86
52 Week low$160.86

Stock Snapshot

As of today, Ascendis Pharma A/S(ASND) shares are valued at $266.92. The company's market cap stands at 16.64B, with a P/E ratio of 28.51.

As of 2026-07-08, Ascendis Pharma A/S(ASND) stock has fluctuated between $266.65 and $273.80. The current price stands at $266.92, placing the stock +0.1% above today's low and -2.5% off the high.

The Ascendis Pharma A/S(ASND)'s current trading volume is 626.37K, compared to an average daily volume of 1.24M.

During the past year, Ascendis Pharma A/S(ASND) stock moved between $160.86 at its lowest and $274.89 at its peak.

During the past year, Ascendis Pharma A/S(ASND) stock moved between $160.86 at its lowest and $274.89 at its peak.

ASND News

TipRanks 22h
Ascendis Pharma price target raised to $280 from $275 at RBC Capital

RBC Capital raised the firm’s price target on Ascendis Pharma (ASND) to $280 from $275 and keeps an Outperform rating on the shares as part of a broader researc...

Simply Wall St 4d
Ascendis Pharma Could Be 7% Undervalued Following Fresh ApproaCH Trial Data

Ascendis Pharma (NasdaqGS:ASND) is back in focus after new Week 104 radiographic data from its pivotal ApproaCH trial of once weekly TransCon CNP in children wi...

Ascendis Pharma Could Be 7% Undervalued Following Fresh ApproaCH Trial Data

Analyst ratings

100%

of 20 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own ASND. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.